ACR Convergence 2025| Video: Rheum for Everyone, Episode 26—Ableism

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: Gout

Aggressive Urate Lowering Needed for Gout

Kathy Holliman  |  July 1, 2010

Patients with gout at increased risk for cardiovascular disease and adverse event

Filed under:Clinical Criteria/GuidelinesConditionsGout and Crystalline Arthritis Tagged with:Cardiovascular diseaseGoutPaintherapyTreatmenturate-lowering therapies

Gout

Staff  |  March 1, 2009

Patient Fact Sheet

Filed under:ConditionsFrom the CollegeGout and Crystalline Arthritis Tagged with:GoutPatient Fact Sheet

Pseudogout

From the College  |  July 1, 2008

Pseudogout is a type of arthritis that, as the name implies, can cause symptoms similar to gout, but which are a reaction to a different type of crystal deposit. This type of arthritis may be one of the most misunderstood forms, and is often mistaken for gout and other conditions, including RA. Proper diagnosis is important because untreated pseudogout may lead to a severe form of joint degeneration and ongoing inflammation, resulting in chronic disability.

Filed under:ConditionsFrom the CollegeGout and Crystalline Arthritis Tagged with:ClinicalDiagnostic CriteriaRA

2008 REF Gout Print to Be Chosen by Ignacio Garcia-De La Torre, MD

Staff  |  February 1, 2008

While attending the ACR Annual Scientific Meeting in Boston, ACR member Ignacio Garcia-De La Torre, MD, visited the ACR Research and Education booth to purchase the latest Rodnan commemorative gout print, A Fisher-King.

Filed under:ConditionsFrom the CollegeGout and Crystalline ArthritisResearch Rheum Tagged with:AC&REducationFellowsGoutREF NewsResearch

Difficult Gout

Robert Terkeltaub, MD  |  July 1, 2007

“Grandpapa’s Torments” was the Rodnan Commemorative Gout Print featured at the 2005 ACR/ARHP Annual Scientific Meeting.

Filed under:ConditionsGout and Crystalline Arthritis Tagged with:Diagnostic CriteriaGoutPathogenesisTreatment

MIPS, MVPs & RISE: The Scoop on Quality Reporting for 2026

Vanessa Caceres  |  November 17, 2025

ACR experts break down MIPS, MVPs & the RISE registry, helping clinicians understand quality reporting requirements for 2026 & beyond.

Filed under:ACR ConvergenceBilling/CodingEMRsLegislation & AdvocacyPractice Support Tagged with:ACR Convergence 2025Centers for Medicare & Medicaid Services (CMS)MACRAMIPSMIPS Value Pathway (MVP)Quality MeasuresQuality Payment Program (QPP)RISE registry

Secrets & Pearls of Rheumatology at ACR Convergence 2025

Mithu Maheswaranathan, MD  |  November 12, 2025

Two clinical diagnosticians presented their pearls of wisdom for clinical rheumatologists to take forward when managing patients from the clinics to the hospital wards.

Filed under:ACR ConvergenceMeeting ReportsMyositisOther Rheumatic ConditionsSjögren’s DiseaseSystemic Lupus ErythematosusVasculitis Tagged with:ACR Convergence 2025ACR Convergence 2025 - LNconnective tissue diseaseLupusLupus nephritismyositisRaynaud’s phenomenonRheumatic DiseaseSjögren's Diseasesystemic lupus erythematosus (SLE)

Calcium Pyrophosphate Deposition Disease Diagnosis & Treatment Gaps Remain

Kurt Ullman  |  November 3, 2025

CPPD diagnosis is difficult & treatments are limited. Experts review radiology challenges, off-label options like colchicine, & emerging biologics.

Filed under:ACR ConvergenceConditionsGout and Crystalline ArthritisGuidanceOsteoarthritis and Bone DisordersResearch Rheum Tagged with:ACR Convergence 2025calcium pyrophosphate deposition diseasechondrocalcinosisColchicinecrystal arthritisprednisonepseudogout

Let’s Discuss Part 2: More Insights from the ACR Convergence 2025 Review Course

Jason Liebowitz, MD, FACR  |  October 28, 2025

The Review Course at ACR Convergence 2025 provided a comprehensive update for practitioners. Highlights from the sections on cutaneous manifestations of rheumatic diseases, gout, macrophage activation syndrome and vasculitis.

Filed under:ACR ConvergenceAmerican College of RheumatologyGout and Crystalline ArthritisMeeting ReportsOther Rheumatic ConditionsSystemic Lupus ErythematosusVasculitis Tagged with:ACR Convergence 2025GoutLupusmacrophage activation syndromeMethotrexatesystemic lupus erythematosus (SLE)Vasculitis

Let’s Discuss: Insights from the ACR Convergence 2025 Review Course

Jason Liebowitz, MD, FACR  |  October 27, 2025

The Review Course at ACR Convergence 2025 provided a comprehensive update for practitioners. Highlights from the sections on SLE and lupus nephritis, inflammatory brain diseases, drug management of rheumatic diseases and mimics of inflammatory myopathies.

Filed under:ACR ConvergenceMeeting ReportsOther Rheumatic ConditionsPediatric ConditionsSystemic Lupus Erythematosus Tagged with:ACR Convergence 2025ACR Convergence 2025 - LNdrugInflammatory Brain DiseasesInflammatory MyopathiesLupusLupus nephritisRheumatic Diseasesystemic lupus erythematosus (SLE)

  • « Previous Page
  • 1
  • …
  • 14
  • 15
  • 16
  • 17
  • 18
  • …
  • 60
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences